Drug intelligence / Profile preview

azathioprine + olsalazine

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of azathioprine, an immunosuppressant, and olsalazine, an anti-inflammatory agent. This combination is primarily used for maintaining remission in steroid-dependent ulcerative colitis. Azathioprine works by inhibiting purine synthesis and disrupting DNA/RNA production in immune cells, while olsalazine delivers mesalamine to the colon where it exerts anti-inflammatory effects by blocking cyclooxygenase-derived products of arachidonic acid metabolism.

Targets

COXTPMT (Thiopurine S-methyltransferase)

Beyond the preview

Go deeper on azathioprine + olsalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azathioprine + olsalazine.

Explore the full profile